TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Chemotherapy combination approaches include the addition of brentuximab vedotin to bendamustine (given the activity of the antibody drug conjugate in ALCL and the safety of the combination from the phase I evaluation in HL), which has shown early signs of activity in CD30-positive PTCL.